शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSECHOKSI LABORATORIES LTD.· Healthcare ServicesHighNeutral
Announced Thu, 13 Aug, 2026 · 15:22 IST

Q1 FY27 results approved; PAT up 51% YoY

Profit growth above 25%Results View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.1%Reaction day
₹117.85
prior close
₹115.95
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.1% vs market
Healthcare Service Provider peers, median of 26sector+0.4%-0.3% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.1+0.2-0.1+0.4-0.3
Next day
+5.0+0.2+4.8-2.1+7.1
2d
+10.3+0.4+9.9-0.8+11.1
3d
+15.7+0.7+15.0-1.8+17.6
4d
+12.0+0.1+11.9-3.2+15.3
5d
+11.2+0.7+10.6-1.5+12.7
1w
+16.9+1.2+15.7-0.7+17.6
15d
+41.2+0.7+40.5-1.0+42.2
1m
+69.7-1.2+70.9-0.9+70.6
2m
+71.4-1.1+72.5-5.7+77.1
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 unaudited results. Revenue from operations rose to Rs 1206.29 lakh vs Rs 1124.19 lakh YoY. Net profit jumped 51% to Rs 58.24 lakh vs Rs 38.50 lakh. EPS at Rs 0.84 vs Rs 0.55. Auditor gave an unqualified review. AGM set for 18 Sep 2026. Reappointed Ms Himika Choksi as Whole Time Director for 5 years.

Likely market impact

Positive - strong PAT growth despite modest revenue increase. Stable governance with director reappointment.